STING Antagonists Offer Tremendous Potential for New Treatments

| By | Bayer, Drug Development

Bayer and Curadev Pvt. Ltd., a drug discovery company based in India, announced a research collaboration and license agreement for Curadev’s Stimulator of Interferon Genes (STING) antagonist program. The collaboration aims to discover new drug candidates for the treatment of lung diseases, cardiovascular diseases and other inflammatory diseases. STING antagonists offer tremendous potential for new treatments as STING is known to play a role in activating the innate immune system in auto-inflammatory diseases.

Curadev’s small molecule STING antagonist program aims to discover and develop inhibitors of the intracellular stimulator of interferon genes (STING) pathway, which can modulate the immune response associated with various auto-inflammatory diseases. As part of the agreement, Bayer will gain exclusive access to novel molecules from Curadev that are designed to inhibit the STING pathway. The companies will collaborate to optimize and advance these molecules, as well as others generated during the collaboration, into clinical development.

Under the terms of the agreement, Curadev will receive an upfront payment. In addition, Curadev will receive research funding during the research term and might be eligible for pre-clinical, clinical and sales milestones of potentially over EUR 250 million as well as royalties of single digit percentages of net sales.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.